Elanco has helped shape the lives of animals and their care providers for more than half a century.

Eli Lilly and Company introduces the first antibiotic exclusively for veterinary use.

New plant and animal science activities are organized and combined into Lilly’s Agricultural and Industrial Sales Division.

Eli Lilly and Company purchases acreage adjoining the Biological Laboratories of Greenfield, Ind. The facility is completed in 1959 and opens as the Agricultural and Veterinary Medicine Research Center.

With the purchase of Corn State Laboratories, Lilly expands its line of veterinary products.

In 1960, Elanco began growing rapidly into new countries and markets.

The Agricultural and Sales Division is reorganized and Elanco Products Company is launched.

Elanco expands its footprint by establishing agricultural units and opening up regional offices.

Elanco continues its global expansion and changes its identity with a bold new logo.

Research and development shifts from plant science toward animal health, specifically on increasing the quality of animal-sourced protein.

A new century brings new changes. Elanco moves its headquarters, acquires new partners and rapidly grows the product portfolio.

Elanco builds dedicated global headquarters campus in Greenfield, Ind., bringing together employees from all areas of the company for the first time.

Elanco requires long-term partner Ivy Animal Health and launches its Pet Animal businesses.

Elanco requires long-term partner Ivy Animal Health and launches its Pet Animal businesses.

Elanco expands its European presence with the acquisition of Janssen Animal Health.

With the acquisition of ChemGen, Elanco obtains. aportfolio of feed enzyme products for poultry, egg and meat production.

Elanco completes the first expansion of its headquarters and establishes ‘hubs’ in international cities. The Pet Animal portfolio grows, and Elanco enters the vaccines sector.

Elanco acquires Lohmann Animal Health and becomes a global leader in poultry.

Elanco acquires Novartis Animal Health. The combined organization is committed to leading the animal health industry in delivering innovation and customer value.

Elanco expands its U.S. pet health portfolio by acquiring an innovative platform of vaccines from Boehringer Ingelheim Vetmedica.

Elanco lists on the New York Stock Exchange (NYSE:ELAN), separating from Lilly and giving its employees ownership.

Elanco becomes a fully-independent pure play animal health company.

Elanco launches its Healthy Purpose™ initiative: its corporate social responsibility platform, and commitment to realizing its vision of Food and Companionship Enriching Life.

Elanco establishes the Elanco Foundation, which is the first-ever haritable foundation in animal health.

Elanco, now with the addition of Bayer Animal Health, has improved capabilities, scale and global reach to position the company as a long-term leader in the growing global animal health market.

As we focus on the future ahead of us, Elanco is committed to animal health and innovation, increasing our ability to deliver for farmers, veterinarians and pet owners.

Elanco employees around the world are working to build a leading animal health company that will make a tangible difference in advancing the health of animals, people and the planet.

Our next era of growth will bring continued growth of our product innovation and purpose-driven culture as we further our vision of Food and Companionship Enriching Life.